Karo Healthcare completes the acquisition of the rights to the Global OTC brand Lamisil® from Haleon

Karo Healthcare (‘Karo’) has today completed the previously announced acquisition of the rights to the Global OTC brand Lamisil® from…

Karo Healthcare acquires the Global OTC brand Lamisil® from Haleon

Karo Healthcare (‘Karo’) announces the acquisition of the rights to the Global OTC brand Lamisil® from Haleon UK Holdings Ltd.…

Babak Peyami Joins Karo’s Corporate Management Team as new Head of Digital Commerce

Karo Healthcare announces changes to its Corporate Management Team. Robin List transitions to an advisory role and Babak Peyami is…

Karo Healthcare publishes the 2022 Sustainability Report

Today, on 24 April 2023, Karo Healthcare is publishing its first separate Sustainability Report on the company’s website, www.karohealthcare.com. For…

Financial Report 2022

Michael Kaltenborn appointed CSDO at Karo

Karo Healthcare (“Karo”) has appointed Michael Kaltenborn as Chief Strategy & Corporate Development Officer (CSDO). The appointment of Michael Kaltenborn…